| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer J Tie, Y Wang, C Tomasetti, L Li, S Springer, I Kinde, N Silliman, M Tacey, ... Science translational medicine 8 (346), 346ra92-346ra92, 2016 | 1511 | 2016 |
| Guidelines for the management of oesophageal and gastric cancer WH Allum, JM Blazeby, SM Griffin, D Cunningham, JA Jankowski, ... Gut 60 (11), 1449-1472, 2011 | 730 | 2011 |
| Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer J Tie, I Kinde, Y Wang, HL Wong, J Roebert, M Christie, M Tacey, R Wong, ... Annals of Oncology 26 (8), 1715-1722, 2015 | 684 | 2015 |
| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer J Tie, JD Cohen, K Lahouel, SN Lo, Y Wang, S Kosmider, R Wong, ... New England Journal of Medicine 386 (24), 2261-2272, 2022 | 668 | 2022 |
| Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer J Tie, JD Cohen, Y Wang, M Christie, K Simons, M Lee, R Wong, ... JAMA oncology 5 (12), 1710-1717, 2019 | 572 | 2019 |
| Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total … A Dewdney, D Cunningham, J Tabernero, J Capdevila, B Glimelius, ... Journal of Clinical Oncology 30 (14), 1620-1627, 2012 | 465 | 2012 |
| Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study J Tie, JD Cohen, Y Wang, L Li, M Christie, K Simons, H Elsaleh, ... Gut 68 (4), 663-671, 2019 | 345 | 2019 |
| A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for … R Wong, D Cunningham, Y Barbachano, C Saffery, J Valle, T Hickish, ... Annals of oncology 22 (9), 2042-2048, 2011 | 272 | 2011 |
| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial SY Rha, DY Oh, P Yañez, Y Bai, MH Ryu, J Lee, F Rivera, GV Alves, ... The Lancet Oncology 24 (11), 1181-1195, 2023 | 241 | 2023 |
| Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN … M Moehler, M Dvorkin, N Boku, M Özgüroğlu, MH Ryu, AS Muntean, ... Journal of Clinical Oncology 39 (9), 966-977, 2021 | 213 | 2021 |
| Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study J Tie, Y Wang, J Cohen, L Li, W Hong, M Christie, HL Wong, S Kosmider, ... PLoS medicine 18 (5), e1003620, 2021 | 153 | 2021 |
| Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer DLH Chan, E Segelov, RSH Wong, A Smith, RA Herbertson, BT Li, ... Cochrane Database of Systematic Reviews, 2017 | 131 | 2017 |
| Targeting DNA damage response and replication stress in pancreatic cancer SB Dreyer, R Upstill-Goddard, V Paulus-Hock, C Paris, EM Lampraki, ... Gastroenterology 160 (1), 362-377. e13, 2021 | 129 | 2021 |
| Cancelled operations: a 7-day cohort study of planned adult inpatient surgery in 245 UK National Health Service hospitals DJN Wong, SK Harris, SR Moonesinghe, SR Moonesinghe, DJN Wong, ... British journal of anaesthesia 121 (4), 730-738, 2018 | 118 | 2018 |
| Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies R Wong, D Cunningham Journal of Clinical Oncology 26 (35), 5668-5670, 2008 | 118 | 2008 |
| HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer H Brunton, G Caligiuri, R Cunningham, R Upstill-Goddard, UM Bailey, ... Cell reports 31 (6), 2020 | 116 | 2020 |
| The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic … T Prasanna, CS Karapetis, D Roder, J Tie, R Padbury, T Price, R Wong, ... Acta Oncologica 57 (11), 1438-1444, 2018 | 110 | 2018 |
| Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial AFC Okines, LC Thompson, D Cunningham, A Wotherspoon, ... Annals of Oncology 24 (5), 1253-1261, 2013 | 108 | 2013 |
| Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies J Tie, JD Cohen, SN Lo, Y Wang, L Li, M Christie, M Lee, R Wong, ... International journal of cancer 148 (4), 1014-1026, 2021 | 101 | 2021 |
| Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology … WH Allum, JM Blazeby, SM Griffin, D Cunningham, JA Jankowski, ... Gut 60 (11), 1449-72, 2011 | 71 | 2011 |
